JUPITER NEUROSCIENCES, INC.
JUPITER NEUROSCIENCES, INC. (JUNS): 1 pipeline candidate. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E -2.42 · 0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for JUPITER NEUROSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.3M
Cash
—
Quarterly Burn
$1.4M
Runway
—
Revenue
$19K
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| jotrol | Phase 2 |
Frequently asked questions
How many drug candidates are in JUPITER NEUROSCIENCES, INC.'s pipeline?
JUPITER NEUROSCIENCES, INC. (JUNS) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is JUPITER NEUROSCIENCES, INC.'s lead drug candidate?
JUPITER NEUROSCIENCES, INC.'s most advanced tracked candidate is jotrol (Phase 2) for Friedreich's ataxia.
What is JUPITER NEUROSCIENCES, INC.'s market capitalization?
JUPITER NEUROSCIENCES, INC.'s market capitalization is approximately $10.3M.
Who is the CEO of JUPITER NEUROSCIENCES, INC.?
Mr. Christer Rosen is the chief executive officer of JUPITER NEUROSCIENCES, INC. (JUNS).
Get the full picture on JUPITER NEUROSCIENCES, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.